United Therapeutics Corporation (UTHR)
$540.03-0.62%Close
BUYRECOVERY · day 40
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $22.9B
- Beta
- 0.56
- P/E (TTM)
- 17.86
- Short % float
- 9.15%
- Days to cover
- 3.6
- SI change
- +28.4%
- 1W
- -0.91%
- 1M
- +7.93%
- vs SPY 1W
- -0.77%
- vs SPY 1M
- +5.42%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 54
- VALUE
- 29
- GROWTH
- 53
- GARP
- 69
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC12.1%
REV YoY-
ROE20.2%
EPS YoY-
ROA18.2%
GROSS86
OP44
NET42
[VALUATION]
P/E TTM17.86
P/E FWD20.18
SECTOR PE20.48
INDUSTRY PE13.99
P/B3.59
P/FCF-
EV/EBITDA12.60
EV/EBIT-
PEG1.29
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO5.73
ND/EBITDA-
BETA0.56
Company news
FAQ
- What is LOPJLB’s current signal on UTHR?
- LOPJLB’s latest quantitative signal on United Therapeutics Corporation (UTHR) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is UTHR in?
- United Therapeutics Corporation (UTHR) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does United Therapeutics Corporation (UTHR) do?
- United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for …